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Introduction
Cancer is one of the leading causes of mortality world  wide, 
having signiﬁ  cant impact on individuals and health  care 
systems. Breast cancer (BC) is one of the top ﬁ  ve cancers 
contributing to overall cancer mortality world  wide, and 
the incidence is predicted to continue to rise [1-3].
Although the causes of BC are widely unknown, 
anthro  pometric, diet and other traits observed at speciﬁ  c 
stages of life have been associated with BC risk. Birth 
weights of 4 kg or more, height, level of obesity, early 
puberty onset and later age at ﬁ  rst pregnancy or nulli-
parity have been positively correlated with BC risk [4-6]. 
Th  ese observations support the notion that timing and 
critical periods of development modify BC risk, which is 
also mirrored in experimental studies [7-9]. Epidemio-
logical studies have provided early clues and highlight the 
impact that our environment, which includes dietary 
factors, has on BC risk.
Asian women, who typically have a low rate of BC and 
a high level of ﬁ   sh oil consumption compared with 
western women, experience an increase in BC incidence 
as well as obesity after emigration to the West. In Asian 
women who have immigrated to the United States, BC 
rates increase to a level equal to westerners within a 
generation, and obesity increases twofold between ﬁ  rst 
and second US-born generations [10-12]. Th  is obser-
vation suggests that the environment, which includes 
changes to dietary habits, may contribute to an increase 
in BC risk and risk factors. Since this change was 
evident in the generation born post emigration, diet 
exposure as early as in utero should be considered a 
factor that modiﬁ   es BC risk. Findings such as these 
provide evidence suggesting that early life exposure to 
environmental factors such as diet may modify disease 
risk later in life.
Dietary factors, including speciﬁ  c classes of fatty acids, 
may be important modiﬁ  ers of BC risk. Dietary fat is 
composed of a complex matrix of fatty acids, with unique 
chemical and biophysical properties that underlie their 
impact on health and disease. Saturated fatty acids (SFA) 
(see Figure 1a), monounsaturated fatty acids (MUFA) 
(see Figure 1b) and trans fatty acids (TFA) (see Figure 1c) 
have all been found to be potentially associated with an 
increase in cancer risk in rodent models [13] and in 
humans [14,15]. Speciﬁ   c polyunsaturated fatty acids 
(PUFA), however, may have anticancer eﬀ  ects. Th  ere  are 
two major classes of PUFA: omega-6 polyunsaturated 
fatty acids (n-6 PUFA) and omega-3 polyunsaturated 
fatty acids (n-3 PUFA). Linoleic acid (LA, 18:2n6) (see 
Figure 1d) and arachidonic acid (AA, 20:4n6) are the two 
most common n-6 PUFA in typical western diets [16,17] 
and have been suggested to have cancer-promoting eﬀ  ects. 
In contrast, n-3 PUFA may have anticancer eﬀ  ects. 
α-Linolenic acid (ALA, 18:3n3) (see Figure 1e) is the 
predominant form of n-3 PUFA in western diets [18]. Th  e 
metabolism of ALA, involving sequential desaturation 
and elongation steps, gives rise to two important long-
chain n-3 PUFA: eicosapentaenoic acid (EPA, 20:5n3) 
(see Figure 1f) and docosahexaenoic acid (DHA, 22:6n3) 
(see Figure 1g). In addition, EPA and DHA can be 
obtained directly from seafood and ﬁ  sh oils [19]. For a 
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A growing body of research focusing on the role of diet 
in early life has emerged; in particular, on the consump-
tion of speciﬁ  c fatty acids and cancer risk. Th   e purpose of 
the present review is therefore to evaluate the linkages 
between dietary fatty acids and cancer risk at diﬀ  erent 
life stages of the lifecycle and the contribution of speciﬁ  c 
families of fatty acids and their individual members. 
Attention will also be given to how speciﬁ  c fatty acids 
modify the development of the mammary gland (MG), 
which may underlie how fatty acids modify the BC risk.
Role of fatty acids in mammary gland development 
and impact on breast cancer risk
Development of the MG is unique and continues 
through  out life. Th   e ductal branching system within the 
MG originates at the nipple with a primary duct that 
extends and branches posteriorly throughout the fat pad 
in childhood at a slow, gradual pace until the onset of 
puberty, at which point the process rapidly accelerates 
[21]. Although the rate of branching is reduced post 
puberty, it continues throughout the reproductive years 
of the female. At the ends of each ductal branch are zones 
of high cell proliferation called terminal ductal lobular 
units, which diﬀ  erentiate into lobuloalveolar units during 
pregnancy and later stages of development [21].
Th  e development of the MG is comparable between 
humans and rodents, thus rodents are often used in MG-
related research [21]. Th  e equivalent structures for 
human terminal ductal lobular units and lobuloalveolar 
units in rodents are terminal end buds (TEB) and alveolar 
buds, respectively [10]. Th   e highly proliferative structures 
have been identiﬁ   ed as the initiation sites in tumori-
genesis [21].
In humans, cessation of branching begins around 
35  years of age or at pregnancy, when diﬀ  erentiation 
occurs and the gland prepares for lactation. Each stage 
may represent a sensitive developmental window during 
which exposure to environmental factors modiﬁ  es BC risk.
Our understanding of mammary carcinogenesis 
continues to advance through basic research using rodent 
models [13,21-24]. Recent evidence suggests that timing 
of exposure to dietary fats is an important factor in 
modulating cancer risk at multiple stages, including in 
utero, prepuberty/puberty, as well as during pregnancy 
and lactation, which are probably periods most sensitive 
to dietary exposure [7-9]. Th  e following sections detail 
Figure 1. Representation of molecular connectivity of diff  erent dietary fatty acid classes. (a) Saturated fatty acids. (b) Monounsaturated fatty 
acids, specifi  cally oleic acid. (c) Trans fatty acids. (d) Polyunsaturated fatty acids, specifi  cally linoleic acid. (e) α-Linolenic acid. (f) Eicosapentaenoic 
acid. (g) Docosahexaenoic acid.
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speciﬁ  c stages throughout the lifecycle.
In utero stage
In utero development may be inﬂ   uenced via maternal 
interaction and exposure to the surrounding environ-
ment. A direct link between the developing fetus and the 
environment is the transfer of placental nutrients from 
the maternal diet. Maternal nutrition is therefore of great 
importance in the development of the fetus, which 
includes the MG.
When pregnant rats were fed high-fat diets using oils 
high in n-6 PUFA, serum estradiol levels increased in the 
mothers and resulted in the female oﬀ  spring  having 
signiﬁ   cantly higher incidence of mammary tumors 
(Table 1) [25,26]. Th  e increase in tumor incidence was 
attributed to changes in the MG of the female oﬀ  spring. 
Th  e eﬀ  ects of the high n-6 PUFA diet were similar to 
animals injected with estradiol during pregnancy, which 
suggests that n-6 PUFA induces adipose cells to produce 
and release estrogen in the body, leading to the promo-
tion of tumor growth [25,26]. Additionally, female 
oﬀ  spring exposed to maternal high-fat diets had earlier 
menarche than controls, which is a marker of increased 
BC risk, and is associated with signiﬁ  cantly  higher 
numbers of TEB (Table 1) [25,26]. Moreover, the MG of 
female rodents exposed to estradiol or a high n-6 PUFA 
diet developed TEB that persisted longer, and with 
reduced diﬀ  erentiation to alveolar buds (Table 1) [25].
In a human study following pregnant mothers’ diets 
and circulating fatty acids and hormone levels, PUFA had 
a signiﬁ  cant positive association with levels of estrogenic 
compounds (Table 2) [27]. When long-chain n-3 PUFA 
levels were examined, however, a signiﬁ  cant  inverse 
relation  ship with estrogenic levels was found (Table 2) [27].
Combined, these factors linked to n-6 PUFA consump-
tion potentially increase the risk of carcinogenesis by 
prolonging the presence of greater numbers of highly 
proliferative cells that are sites for tumorigenesis. When 
high-fat n-6 PUFA diets were co-supplemented with n-3 
PUFA via ﬁ  sh oil during pregnancy in rats, a decrease in 
BC risk in the oﬀ  spring was observed (Table 1) [28], 
suggesting that maternal intake of PUFA requires an 
optimal balance between n-6 PUFA and n-3 PUFA to 
mitigate the BC risk.
Th   e opposing eﬀ  ects of these families of PUFA relate to 
their competition for similar enzymes involved in their 
metabolism, including desaturases, elongases and 
enzymes involved in eicosanoid synthesis such as cyclo-
oxygenases and lypoxygenases. Th  e metabolism of n-6 
PUFA produces proinﬂ   ammatory eicosanoids such as 
prostaglandin E2, but the presence of n-3 PUFA inhibits 
their synthesis [29]. Th   e ratio of n-6/n-3 PUFA is thus of 
considerable importance. Th   ere is some controversy as to 
whether or not this fatty acid ratio is truly important [30], 
but historical trends suggest that a lower n-6/n-3 ratio is 
potentially associated with a decreased incidence of 
cancer [31,32].
Birth to pubescence
Physical status at birth as well as early nutritional intake 
are potentially telling of future cancer risk. Studies have 
shown that high birth weights of 4 kg or more are 
positively associated with BC risk, nearly doubling the 
risk when compared with normal weights of 2.5 to 2.9 kg 
(Table 1) [5,33,34]. n-6 PUFA consumption has been 
shown to be positively associated with birth weight in 
humans [27].
Breastfeeding has been shown to reduce an infant’s 
risk of developing BC before menopause by up to 35% 
(Table 1) [33]. Th  e long-chain PUFA DHA, present in 
breast milk, is known to be important for supporting 
neuronal and visual development, constituting, on 
average, 2.88% of an infant’s total energy (Table 1) [35]. 
As will be discussed, the presence or supply of DHA at 
this early stage of life may also impact on the long-term 
development of the MG and consequently modify 
future cancer risk. Th  e supply of DHA is further 
modiﬁ   ed by maternal intake of TFA, which may 
interfere with DHA synthesis, thus reducing the DHA 
concentration in breast milk (Table 1) [36]. As DHA 
plays an important role in fetal development, 
interactions such as these stress the importance of being 
aware of interactive eﬀ   ects between diﬀ  erent  fatty 
acids  – particularly in the maternal diet, as negative 
eﬀ  ects on fetal development can result.
Th  e literature on estrogenic eﬀ  ects during prepubes-
cence is more complex than that for other developmental 
stages. Estrogen in rodent fetal development translates to 
an increase in BC risk [25,26], but studies in both humans 
[37] and rodents [8,38] indicate that estrogen may be 
protective in the prepubescent period. Rat studies have 
shown that continuous postnatal exposure to estradiol 
during the ﬁ  rst 30 days after birth decreases the suscep-
tibility of the MG to carcinogen-induced tumorigenesis 
(Table 1) [39,40]. Similar eﬀ  ects have been observed on 
the MG when estradiol exposure is replaced with high 
n-6 PUFA diets (Table 1) [8]. Additionally, fat intake and 
a high body mass index surrounding puberty, which is 
correlated with increased production of estrogens, have 
been linked to MG development [8]. It has been reported 
that a higher body mass index during childhood and 
adolescence reduces the risk of both premenopausal and 
postmeno  pausal BC (Table 1) [8,37,41,42]. Some studies, 
however, suggest no association exists between high body 
mass index during childhood or adolescence and BC risk 
[43]. Adding to the complexity of eﬀ  ects at this stage, 
higher childhood body mass index is linked to early 
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risk (Table 1) [4,45].
Th  e type of fat consumed is also another modifying 
factor in this complex relationship. A rodent study that 
provided high n-6 PUFA diets to rats during various stages 
of life found that all rats exposed to the high n-6 PUFA 
diets in utero or postnatally prior to pubescence experi-
enced a signiﬁ  cant increase in mammary tumor incidence, 
when compared with rats that were only ex  posed to high 
n-6 PUFA post puberty (Table 1) [9]. When considering 
long-chain n-3 PUFA, there is an inverse association with 
estrogenic levels (Table 2) [27], which may be beneﬁ  cial to 
the MG during early developmental stages. Consuming a 
low-fat n-3 PUFA diet during pre  pubescence resulted in a 
protective eﬀ  ect against mammary carcinogenesis in rats 
(Table 1) [46]. In contrast, in the same study, a high-fat n-3 
PUFA diet led to lower TEB numbers relative to n-6 PUFA 
controls, but immunohistochemistry revealed that cells 
comprising the TEB had higher levels of cell proliferation 
and increased incidence of mammary tumorigenesis 
(Table 2) [46]. Such observations may be attributable to 
the overall high fat content of the diet, as high-fat diets 
have been linked to mammary tumors that have increased 
protein kinase C activity [47-49].
Pregnancy and late-stage mammary gland development
Pregnancy and lactation is a time of considerable re-
model  ing of the MG in the mother. During pregnancy, 
the breast tissue undergoes rapid proliferation followed 
by diﬀ  erentiation in preparation for lactation [50]. Th  e 
timing of ﬁ  rst pregnancy has been observed to aﬀ  ect BC 
risk, which may be due to the accumulation of mutations. 
First pregnancy later in life results in more time having 
elapsed for mutations to develop, which become potential 
tumor sites in the developing MG [45]. In fact, if the ﬁ  rst 
full-term pregnancy occurs before the age of 18, BC risk 
is decreased to 40% that of nulliparous women (Table 1) 
[4,50]. In contrast, having a ﬁ  rst birth after 35 years of 
age increases risk by 20% over nulliparous women [50]. A 
maternal diet high in fat increases BC risk for the mother 
by raising estrogenic levels (Table 1) [26]. In addition, 
high pregnancy weight gain, where women gained more 
than the recommended 11 to 15 kg throughout preg-
nancy, increased risk by 62% (Table 1) [45].
Eff  ect of fatty acids on breast cancer
Depending on the type, fatty acids may diﬀ  erentially 
promote BC or, alternatively, may play a role in inhibiting 
BC. Cell culture studies have found that SFA, MUFA and 
n-6 PUFA promote BC cell growth [13], whereas ALA, 
EPA and DHA inhibit BC cell growth [51-53] (Table 2).
An exception within the MUFA class is oleic acid 
(18:1n9) (see Figure 1b), which has been shown to exert 
anti-tumorigenic eﬀ  ects by suppressing overexpression 
of human epidermal growth factor receptor-2 (HER2) 
(Table 2) [54]. Additionally, oleic acid intake levels are 
Table 1. Diet-related factors eff  ecting mammary gland development in critical periods of development
Time period  Eff  ect  Reference
In utero  n-6: decreased number of alveolar buds in female off  spring  [25]
  n-6: increased incidence of mammary tumors  [25,26]
  n-6: earlier menarche of female off  spring  [25,26]
  n-6: increased number and duration of TEB in female off  spring  [25,26]
  n-3: decreased BC risk in female off  spring  [28]
Lactation  Breastfeeding decreased infant’s BC risk   [33]
  DHA in breast milk important for fetal development  [35]
  Maternal trans fatty acid consumption decreased DHA levels in milk  [36]
Birth to pubescence  Birth weight >4 kg increased risk of BC  [5,33,34]
  Earlier menarche increased risk of BC  [4,45]
  Higher body mass index decreased risk of BC  [8,37,41,42]
  Estradiol exposure decreased risk of mammary tumors  [39,40]
  n-6: decreased mammary tumorigenesis   [8]
  n-6: increased mammary tumor incidence  [9]
  n-3: decreased number of TEB  [46]
Pregnancy  Later fi  rst pregnancy increased mother’s risk of BC  [4,50]
  High-fat diet increased mother’s risk of BC  [26]
  Weight gain >15 kg increased mother’s risk of BC  [45]
BC, breast cancer; DHA, docosahexaenoic acid; TEB, terminal end buds.
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levels [55].
Th   e n-6 PUFA, including LA and AA, are observed to 
promote a tumor-enhancing environment in the MG 
(Table 2) [16,46]. AA is a long-chain n-6 PUFA, linked to 
cell proliferation within the MG, and is associated with 
enhancing early stages of angiogenesis (Table 2) [16]. AA 
is the direct precursor of eicosanoids, which mediate 
proinﬂ  ammatory processes contributing to tumorigenesis 
in women [29] and in female rodents [56] (Table 2). 
Table 2. Eff  ects of dietary fatty acids on breast cancer risk
Fat type  Eff  ect  Reference
SFA  Increased risk of BC  [13,95]
  Compromise cell response to DNA damage  [94]
TFA  Positively associated with mammary tumors  [14]
 Eff  ect similar to cis fats on BC  [96]
  Conjugated linoleic acid supplements inhibit cancer cell growth  [97,98]
MUFA  Increased risk of BC  [13]
  Oleic acid suppresses HER2 in BC cells  [54]
n-6 PUFA  Promote mammary tumor growth  [13]
  Increased cell proliferation in mammary gland  [16]
  Protumorigenic in mammary gland  [16,46]
  Increased circulating estrogenic compound levels  [27]
  Promote tumorigenesis via infl  ammation  [29,56]
  Positively associated with HER2 oncogene  [52,57]
n-3 PUFA  Decreased circulating estrogenic compound levels  [27]
  Decreased mammary tumor incidence/growth rate (low-fat dose)  [46]
  Increased tumor cell proliferation and growth rate (high-fat dose)  [46]
  Decreased BC cell growth  [51-53]
  Inhibit HER2 expression  [57]
  Inhibit mammary tumor growth  [58,59]
 Increased  apoptosis  [62]
  Decreased tumor growth rate  [63]
  Decreased tumor cell proliferation; increased apoptosis  [67-70]
  Increased syndecan-1 synthesis  [74]
  Decreased premenopausal/postmenopausal BC risk  [80,85-89]
  Fish oil consumption decreased BC risk  [86]
ALA  Strongly suppresses HER2 and mammary carcinoma  [52]
  Promotes regression of estrogen receptor+ MCF-7 cancer  [60]
  Signifi  cantly slows tumor growth rate  [61]
  Inversely associated with BC risk (natural sources)  [99]
  Positively associated with BC risk (processed sources)  [99]
EPA  Slows mammary tumor growth rate  [53]
  Inhibits lung metastases; decreased eicosanoids  [64]
  Suppresses cell proliferation in MCF-7 cells  [76]
DHA  Enhances treatment eff  ect of taxanes  [51]
  Reduces cell viability in some cancer cell lines  [51]
  Downregulation of HER2  [52]
  Higher tumor regression than other n-3 PUFA  [77]
ALA, α-linolenic acid; BC, breast cancer; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HER2, human epidermal growth factor receptor-2; MUFA, 
monounsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acids; n-6 PUFA, omega-6 polyunsaturated fatty acids; SFA, saturated fatty acids; TFA, trans 
fatty acids.
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associated with the HER2 oncogene, present in 40% of 
BC cases (Table 2) [52,57].
In contrast, n-3 PUFA have been shown to reduce the 
risk of mammary carcinogenesis (Table 2) [58,59]. Cell 
culture work found that ALA strongly suppressed over-
expression of HER2-positive mammary carcinomas 
(Table 2) [52]. Th   e use of ﬂ  axseed treatments (57% ALA) 
on MCF-7 cells in ovariectomized mice produced a 
signiﬁ  cant reduction in tumor growth when compared 
with a diet containing no ﬂ  axseed (Table 2) [60]. In con-
junction with these eﬀ  ects, it was found that ﬂ  axseed 
consumption actually enhanced the inhibitory eﬀ  ects of 
tamoxifen, a drug used in BC treatment [60]. A study on 
mice treated with MDA-MB-231 BC cells comparing 
diets of corn oil (1% ALA) with diets of canola oil (10% 
ALA) found the tumor growth rate to be signiﬁ  cantly 
reduced in canola-fed mice (Table 2) [61].
Th  e n-3 PUFA are thought to be linked to increased 
susceptibility to peroxidative damage, leading to cell 
death (Table 2) [62]. In one study, when compared with 
an n-6 PUFA diet, the n-3 PUFA diet decreased the 
tumor growth rate by 66% in mice carrying human BC 
xeno  grafts (Table 2) [63]. Th  ese beneﬁ   ts are seen 
particularly with the long-chain n-3 PUFA EPA and 
DHA, which occur in high concentrations in ﬁ  sh oils 
[29,59,64]. Despite these supportive studies, a few limited 
studies on rodents [13] and humans [65,66] have shown 
that ﬁ  sh oil and n-3 PUFA are not always consistently 
shown to inhibit BC.
Little is known in terms of the mechanistic pathways by 
which n-3 PUFA inhibit cancer growth, but several 
mecha  nisms have been proposed. EPA and DHA have 
both been found to inhibit the production of AA-derived 
eicosanoids in tumors [64]. Lipid peroxidation, which 
induces apoptosis, is another potential mechanism by 
which n-3 PUFA suppress cell proliferation in tumors 
(Table 2) [62,  67-70]. Numerous experimental studies 
have looked at apop  totic eﬀ  ects induced by n-3 PUFA 
mediated by peroxi  some proliferator-activated receptor 
gamma (PPARγ) [57,  62,    67,68,71-74]. n-3 PUFA bind and 
activate PPARγ, lead  ing to activation of the proteoglycan 
syndecan-1 in human BC cells, which promotes apoptosis 
leading to cell growth inhibition [73,74]. n-3 PUFA 
containing low-density lipoproteins deliver both EPA and 
DHA to cells and cause a signiﬁ  cant twofold increase in 
syndecan-1 synthesis (Table 2) [74]. Th  ese mechanistic 
studies help to explain potential mechanisms by which n-
3 PUFA inhibits cancer cell growth, which supports a role 
for n-3 PUFA as an eﬀ   ective means of treating BC. 
Further investigation is necessary, however, as a study 
conducted recently showed that both the amount and 
type of fatty acid have an impact on cellular activity, with 
low-fat n-3 PUFA diets decreasing cell proliferation via 
PPARγ expression and high-fat n-3 PUFA diets increasing 
cell proliferation via cyclin D1 expression [75].
Fish oil is a mixture of EPA and DHA, and speciﬁ  c 
individual eﬀ  ects of each fatty acid remain to be fully 
clariﬁ  ed. In support of EPA as the principal eﬀ  ector, a 
study examining cancer progression in mice with induced 
mammary tumorigenesis found that 4% EPA in the diet 
had greater eﬃ     cacy than 4% DHA in inhibiting lung 
metastases (Table 2) [64]. EPA was also found to suppress 
an inhibitory G protein-coupled free fatty acid receptor-
mediated signal trans  duction pathway involved in cell 
proliferation in MCF-7 cell xenografts on mice (Table 2) 
[76]. Moreover, EPA was observed to slow the tumor 
growth rate and to reduce metastasis when an EPA diet 
was compared with a LA diet in mice inoculated with 
KPL-1 human BC cells (Table 2) [53]. Evidence of DHA 
being the primary eﬀ  ector in inhibiting tumorigenesis 
was observed in patients with localized BC. In this study, 
adipose tissue with high concentrations of DHA showed 
the greatest extent of tumor regression (Table 2) [77]. 
DHA itself has also been linked to downregulation of the 
HER2 onco  gene (Table 2) [52] and to the reduction of 
cancer cell viability (Table 2) [51]. Additionally, DHA has 
been shown to synergistically enhance the cytotoxic 
activity of taxanes, in some cases by up to 13-fold (Table 
2) [51]. Recent research has shown that DHA is the 
precursor to potent lipid mediators, identiﬁ  ed  as 
resolvins, that regu  late inﬂ   ammation [78,79]. Further 
attention is warranted in order to distinguish and 
understand the eﬀ  ects of individual n-3 PUFA.
Human studies and n-3 PUFA
While a considerable amount of cell culture and animal-
based research suggests that n-3 PUFA may modify BC 
risk and provide protection against mammary tumori-
genesis [8,46,59,80,81], human cohort, case–control 
studies have failed to provide similar strong support, 
often ﬁ  nding null relationships between EPA and DHA 
consumption and BC risk [19,82-84]. Nevertheless, a 
limited number of studies support a beneﬁ  cial relation-
ship between n-3 PUFA and BC risk, many of which are 
conducted in Asian populations that typically consume 
higher levels of n-3 PUFA (Table 2) [80,85-89]. One could 
argue that if such a beneﬁ  cial eﬀ  ect truly existed then it 
should be quite obvious. Th  e wide disparity in ﬁ  ndings 
may reﬂ  ect methodological limitations, speciﬁ  cally the 
use of dietary measures reliant on self-reports that are 
often biased [8,13,26,49,90-92]. Moreover, North American 
populations may not be the most appropriate study 
population for epidemiological research to investigate the 
link between n-3 PUFA and BC, as the dynamic range 
between low consumers and high consumers is not very 
great and is therefore too low to elicit any health beneﬁ  ts, 
as compared with studies conducted in Asian countries 
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on Korean women found BC risk in both premenopausal 
women and postmenopausal women to be reduced with 
EPA and DHA consumption (Table 2) [80]. Furthermore, 
longitudinal studies have only focused on dietary eﬀ  ects 
in adulthood; potential eﬀ   ects during pregnancy/fetal 
developmental period and puberty have therefore yet to 
be rigorously examined.
Another factor that may contribute to the disparity 
between North American and Asian studies is the source 
of dietary n-3 PUFA. While Asian countries have higher 
intake of marine foods containing EPA and DHA, the 
North American diet contains mainly ALA. Conversion 
of ALA to EPA and DHA is limited in humans, yielding 
only ~5.0% and ~0.5%, respectively [19]. Unfortunately, 
despite numerous dietary options, daily intake of ALA in 
North American women is low, in some instances 
averaging less than one-half of their recommended intake 
of 1.1 g/day [19,93]. Additional research is needed to 
determine the speciﬁ  c biological eﬀ  ects of ALA, EPA and 
DHA in order to ascertain their relative eﬀ  ectiveness in 
modifying BC risk.
Th  e eﬀ  ects of other fatty acids on BC, including SFA, 
MUFA and TFA, in human studies are also limited. Studies 
conducted on BC cell lines and rodents have shown SFA to 
promote carcinogenesis by inhibiting cellular responses to 
DNA damage (Table 2) [13,94], and SFA consumption in 
humans is observed to be associated with increased BC 
risk (Table 2) [95]. What is not clear, however, is whether 
these are truly direct eﬀ  ects of SFA or a marker of a poor 
diet and obesity, which is associated with cancer risk. A rat 
study comparing trans and cis fatty acids showed no 
signiﬁ  cant diﬀ  erence between groups (Table 2) [96]. In 
contrast, French data from a large-scale European health 
and nutrition prospective cohort study (Etude 
Epidémiologique de femmes de la Mutuelle Générale de 
l’Education Nationale (E3N) 1989–2002) found that BC 
risk was positively associated with TFA, but was not 
associated with cis-MUFA (Table 2) [14]. Despite negative 
connotations with TFA to human health, conjugated LAs 
are an exception. Conjugated LAs, naturally occurring 
TFA found in ruminant fat products such as dairy and beef 
products, have been shown to exert anti-carcinogenic 
eﬀ  ects in BC cell lines and animal models (Table 2) [97,98]. 
Further studies conducted on E3N data found ALA to be 
inversely associated with BC risk, but only when the 
source was from vegetable oils or fruits and vegetables 
(Table 2) [99]. Conversely, an increase in BC incidence was 
noted in relation to ALA when it was obtained through 
processed foods (Table 2) [99].
Directions for future research
Th  e present review has outlined the widely varying 
eﬀ  ects dietary fatty acids have on MG development and 
BC. Th  ere remains much inconsistency in the literature 
regarding the eﬀ  ects of speciﬁ  c classes of fatty acids and 
their role in BC. Th   e lack of support may not truly be due 
to a lack of eﬀ  ect, but rather to a lack of our under  stand-
ing of temporal eﬀ  ects and of speciﬁ  c dietary fatty acids 
during critical periods of development. Most promising 
is the ability of n-3 PUFA to alter MG development in the 
early stages of life, thus protecting against mammary 
tumorigenesis later in life. Th   e role of dietary fat in BC is 
indeed a complex relationship. Given that there is 
mechanistic evidence and emerging data supporting a 
role for nutrition during pregnancy and early stages of 
life that modify BC risk, further investi  gations are 
warranted. A better appreciation for diet during early life 
and critical periods of development may help enhance 
our ability to conduct more rigorous human studies to 
ascertain the eﬀ   ect of dietary components in the 
development of BC.
Th  is review identiﬁ   es evidence suggesting that n-3 
PUFA may have a beneﬁ  cial role for both the prevention 
and treatment of BC. Future research in this ﬁ  eld should 
focus on the eﬀ  ect of early n-3 PUFA exposure on long-
term BC risk, targeting early critical windows in develop-
ment as discussed throughout the present review. 
Further  more, a closer look at the role of individual fatty 
acids in MG development and BC risk, speciﬁ  cally ALA-
enriched, EPA-enriched and DHA-enriched diets, is 
justiﬁ  ed to elucidate diﬀ  erential eﬀ  ects. Such studies are 
warranted since prevention of BC, as opposed to 
treatment modalities, will not only have the most impact 
for individuals but is also economically sustainable.
Overall, the present review highlights additional 
complex  ities underlying the relationship between diet 
and BC and new directions for future research to improve 
our understanding of the role of dietary fatty acids in BC 
prevention and treatment.
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